Alerta

CCDC71L在诊断及治疗放射性肠炎中的应用

Resumen de: CN119433017A

The invention discloses an application of CCDC71L in diagnosis and treatment of radiation enteritis, and provides an application of a reagent for detecting the expression level of the CCDC71L in preparation of a product for diagnosing radiation enteritis and an application of an inhibitor of the CCDC71L in preparation of a medicine for treating radiation enteritis. The invention further provides a method for screening candidate drugs for treating or preventing radiation enteritis and a method for inhibiting the expression level of inflammatory factors in macrophages. Experiments prove that the CCDC71L can realize diagnosis of radiation enteritis, and discovers that inhibition of the CCDC71L can inhibit infiltration and polarization of macrophages so as to inhibit radiation-induced inflammatory reaction, and the CCDC71L marker provided by the invention provides a new idea for diagnosis and treatment of radiation enteritis, and has a wide application prospect.

BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITIS

Resumen de: EP4663746A2

This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.

METHOD FOR MONITORING AND EVALUATION OF BOWEL HEALTH IN PREMATURE NEWBORNS

Resumen de: US20260022426A1

Disclosed is a method for monitoring and evaluation of bowel health in premature newborns. The method involves collecting stool/fecal samples from premature newborns/babies and processing the sample using microbiomics, automated cell counting, flowcytometry, and RT PCR analysis using specific gene signature or RNA transcriptomics analysis to determine risk of necrotizing enterocolitis. The method allows evaluation and tracking of gut health without needing to draw a blood test and is a non-invasive method. The method diagnoses and prevents bowel inflammation, infection and necrotizing enterocolitis (NEC) that facilitates initiation of prompt therapy to limit morbidity and mortality in premature babies. The method facilitates early management of signs of NEC thereby helping to save lives of premature babies and infants having low birth weight.

C3-HNE ASSAY

Resumen de: AU2024275955A1

The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.

SEROLOGY REPERTOIRE FOR THE DIAGNOSIS AND PROGNOSIS OF INFLAMMATORY BOWEL DISEASE

Resumen de: WO2026020057A1

This disclosure provides for method for the diagnosis, prognosis and treatment of inflammatory bowel disease (IBD) and clinical subtypes of IBD in a subject by detecting the presence or level of one or more immune responses to self and microbial antigens in a sample from a subject.

METHOD FOR DETERMINING INTESTINAL PERMEABILITY

Resumen de: CN120936879A

The present invention relates to an in vitro method for assessing the state of intestinal permeability in a subject and thus for diagnosing a disease or dysfunction associated with hyperintestinal permeability. More specifically, the procedure allows the amount of dietary antigens that can pass through the dysfunctional intestinal tract to be measured using common food components. The program allows for the development of analytical products and processes within the framework of the medical instrument industry.

C3-HNE 분석법

Resumen de: AU2024275955A1

The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.

COMPOSITIONS, DEVICES, AND METHODS OF CROHN'S DISEASE SENSITIVITY TESTING

Resumen de: US20260016486A1

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

METHOD AND SYSTEM FOR THE DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE (IBD)

Resumen de: AU2024283890A1

The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE

Resumen de: AU2024307935A1

Aspects of the disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBDs"), such as ulcerative colitis ("UC") and/or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an exterior surface of the core. In some cases, the protease inhibitor is a gliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and/or small intestine of a subject to whom the pharmaceutical dosage form is administered. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., a bacterial protease) to the large intestine (e.g., colon) and/or small intestine of a subject.

METHODS FOR REDUCING DRUG-INDUCED LIVER INJURY

Resumen de: US20260008842A1

The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.

Crohn disease focus automatic segmentation and activity evaluation system based on deep learning

Resumen de: CN121280339A

The invention discloses a Crohn disease focus automatic segmentation and activity evaluation system based on deep learning, which belongs to the field of medical artificial intelligence and comprises a data preprocessing unit, a focus automatic segmentation unit, a radiomics feature extraction unit, a feature screening and dimension reduction unit and an activity classification unit. According to the method, an nnU-Net deep learning segmentation model is combined with image omics feature extraction, multi-stage feature screening and machine learning classification technologies, so that full-process automation from CTE image preprocessing, focus automatic segmentation, feature extraction and screening to activity classification is realized. The system can efficiently and accurately segment the focus of Crohn's disease, automatically assesses the disease activity based on the screened key radiomics characteristics, significantly improves the consistency, objectivity and efficiency of diagnosis, and is suitable for clinical auxiliary diagnosis and scientific research analysis.

CD early screening marker based on plasma proteomics, application and early screening kit

Resumen de: CN121276058A

The invention provides a Crohn disease early screening marker based on plasma proteomics. The early screening marker comprises the following nine proteins: CD274, CHI 3L1, REG1B, ITGAV, PRSS8, ITGA11, GDF15, DEFA1DEFA1B and IL6. The early screening marker provided by the invention can accurately and non-invasively predict CD as long as 16 years before diagnosis, which provides an important value for early screening of CD high risk groups and formulation of intervention measures. The invention also provides application of the Crohn disease early screening marker and an early screening kit for Crohn disease prediction.

Mucous membrane healing evaluation method based on energy spectrum CT iodine quantification

Resumen de: CN121242609A

The invention discloses a mucous membrane healing evaluation method based on energy spectrum CT iodine quantification, and belongs to the field of medical image processing and clinical diagnose.The mucous membrane healing evaluation method comprises the following steps that an energy spectrum CT intestinal stage scanning image of a patient suffering from Crohn's disease is obtained, and a three-dimensional volume area of a diseased intestinal segment is delineated on an energy spectrum CT iodine substance decomposition graph; selecting a reference blood vessel area, and measuring an iodine concentration value; calculating a normalized iodine concentration value, wherein the normalized iodine concentration value is equal to a result obtained by dividing the iodine concentration value of the lesion intestinal segment by the iodine concentration value of the reference blood vessel region; and comparing the normalized iodine concentration value with a preset threshold value 0.44, if the normalized iodine concentration value is less than 0.44, determining that the mucous membrane is healed, otherwise, determining that the active inflammation is caused. According to the scheme, traditional invasive enteroscopy is replaced with energy spectrum CT image analysis, contraindications of endoscope operation, patient pain and examination blind areas are avoided, the acceptability and examination feasibility of patients are remarkably improved, and the method is particularly suitable for p

ORAL-GUT-BRAIN AXIS VIROME/MICROBIOME FOR PERIODONTITIS, IRRITABLE BOWEL DISEASE AND ALZHEIMER'S DISEASE DIAGNOSTICS

Resumen de: WO2026006246A1

The disclosure provides an evaluation of the virome in health and disease of the oral-gut-brain axis, in particular, periodontitis, irritable bowel disease (IBD) and Alzheimer's Disease (AD). For Alzheimer's disease, a striking feature was found via metagenomics of brain autopsy specimens - the presence of parvoviridae (comprised of erythoviruses and erythroparvoviruses) in the brains of individuals diagnosed with Alzheimer's Disease (AD) but not in brains from age-matched healthy individuals without a medical diagnosis of AD. For IBD, For Periodontitis and IBD, an analysis revealed the top 20 most abundant viral and bacterial species in saliva samples from individuals with periodontal disease or with a healthy periodontium and the top viral and bacterial species in stool samples from individuals with irritable bowel syndrome or with gastrointestinal health. Building upon these discoveries, a number of diagnostic methods and materials for AD and IBD are described herein.

Application of DDX24 in maintaining homeostasis of intestinal vascular barrier

Resumen de: CN121249871A

The invention belongs to the technical field of molecular biology, and discloses application of DDX24 in maintaining the homeostasis of an intestinal vascular barrier. According to the present invention, the low expression of the intestinal microvascular endothelial DDX24 in the inflammatory bowel disease (IBD) is firstly found so as to construct the adult endothelial cell specific DDX24 induced knockout mouse model, the homeostasis of the intestinal vascular barrier (GVB) of the mouse is imbalanced, and the mouse suffers from spontaneous enteritis, such that the intestinal microvascular endothelial cell DDX24 is the important molecule for maintaining the intestinal homeostasis; and mechanism research finds that the intestinal microvascular endothelial cell DDX24 inhibits cell senescence to protect the GVB steady state. The research discloses an important mechanism of DDX24 for protecting GVB homeostasis by inhibiting intestinal microvascular endothelial cell senescence for the first time, and provides a strategy and basis for clinical diagnosis and treatment of IBD vascular barrier.

MICROBIAL METABOLITES ON INTESTINAL INFLAMMATION

Resumen de: US20260000713A1

Provided herein are methods of predicting a likelihood that a subject will develop ileitis, intestinal fibrosis or colitis based on an amount of acetate or acetate-producing bacteria detected in a sample obtained from a subject. Certain genetic risk variants at TNF super-family member 15 (TNFSF15) may also be detected. Methods, systems and kits for treatment of develop ileitis, intestinal fibrosis or colitis are also provided, which include inhibitors of acetate or acetate-producing bacteria, or targeting biologic therapeutics, such as inhibitors of Tumor necrosis factor (TNF)-like cytokine 1A (TL1A).

REGULATION OF GENES IN ULCERATIVE COLITIS AND THE USES THEREOF

Resumen de: TW202535470A

The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/ or diagnostic use in a subgroup of patients having ulcerative colitis.

REVERSIBLE BACTERIAL PHSE-VARIATIONS AND USES THEREOF IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS

Resumen de: WO2024176230A1

The present disclosure relates to reversible phase variations in bacteria e.g., residing in a microbiome or any environment, and uses thereof in determining a physiological and/or environmental condition or state of a subject or a media and/or or habitat. The present disclosure thus provides methods and personalized therapeutic methods and kits.

Noninvasive intestinal flora fixed-point sampling and drug release device

Resumen de: CN121196614A

The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.

METHODS FOR ASSESSING MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE PATIENTS

Resumen de: US2025389717A1

The present disclosure provides methods for assessing mucosal healing in a patient with Crohn's Disease. The methods include detecting expression levels of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

Lactolipoprotein A2 and related isoforms for treatment of autoimmunity and inflammation

Resumen de: CN121194794A

Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are methods of increasing T regulatory (Treg) cells or decreasing T helper 17 (Th17) cells. The methods involve administering to the subject a lactophilic lipoprotein A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing. These methods are useful for treating diseases with autoimmune and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, autoimmune or inflammatory nervous system disease, antibody-mediated transplant rejection, infant cholestasis, hemophagocytic lymphocythemia, erythrocytophagocythemia, malnutrition, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia and hyperplasia. The traditional Chinese medicine composition is beneficial to patients suffering from systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.

C4A3-HNE和C4A4-HNE测定

Resumen de: AU2024213780A1

Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.

C3-HNE测定

Resumen de: WO2024240709A1

The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.

METHODS FOR THE DETECTION OF CIRCULATING MICROCLOTS AND NEUTROPHIL EXTRACELLULAR TRAPS IN INFLAMMATORY CONDITIONS

Nº publicación: WO2025257752A1 18/12/2025

Solicitante:

UNIV DE MONTPELLIER [FR]
INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE [FR]
INST REGIONAL DU CANCER DE MONTPELLIER [FR]
STELLENBOSCH UNIV [ZA]
UNIVERSITE DE MONTPELLIER,
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE,
INSTITUT REGIONAL DU CANCER DE MONTPELLIER,
STELLENBOSCH UNIVERSITY

Resumen de: WO2025257752A1

This invention relates to methods of detecting inflammatory disease in a subject by detecting circulating microclots, based on combined detection or co-detection of fibrin amyloid microclots and components from Neutrophil Extracellular Traps in a sample from the subject, wherein an increased presence of fibrin amyloid microclots and NETs in the sample compared to a control or reference value is indicative of inflammatory disease in the subject. The invention also relates to kits for detecting circulating microclots to be used in the methods of detecting inflammatory disease.